Contracting triple-negative breast cancer with immunotherapeutic armamentarium: recent advances and clinical...

Area of Science:

• Oncology
• Immunology
• Biomarker Discovery

Background:

• Triple negative breast cancer (TNBC) is an aggressive subtype with limited treatment options, primarily chemotherapy.
• Chemotherapy resistance and recurrence necessitate novel therapeutic strategies.
• circ-HER2 expression in some TNBC cases presents a potential immunotherapy target.

Purpose of the Study:

• To review potential molecular biomarkers for immunotherapy in TNBC.
• To examine clinical trials of immunotherapy in various TNBC settings (neoadjuvant, adjuvant, metastatic).
• To explore targets for therapeutic vaccines in TNBC.

Main Methods:

• Literature review of immunotherapy in TNBC.
• Analysis of clinical trial data for immunotherapy efficacy and safety.
• Identification of potential molecular targets for drug development and vaccines.

Main Results:

• Immunotherapy demonstrates positive application in TNBC, despite potential adverse events.
• circ-HER2 is identified as a promising immunotherapy target.
• Evidence from clinical trials supports immunotherapy's role in TNBC treatment.

Conclusions:

• Immunotherapy offers a promising avenue for treating TNBC, with careful risk-benefit assessment.
• Targeting molecular biomarkers like circ-HER2 can guide future drug development.
• Further research into therapeutic vaccines is warranted for TNBC management.